leadf
logo-loader
viewAmryt Pharma PLC
(
AIM:AMYTNASDAQ:AMYTFRA:3N9
)

Amryt reports record 2Q results and raises full-year guidance as momentum continues to build

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT, FRA:3N9) CEO Joey Wiley joined Proactive’s Stephen Gunnion to discuss the company's second-quarter results, which show a 35.9% rise in revenue year-on-year.

Wiley noting that it's the sixth consecutive quarter the company has reported positive EBITDA (core earnings) generation.

Given the strong performance year to date, Amryt has also raised its full-year 2021 revenue guidance to $210-$215 million.

Quick facts: Amryt Pharma PLC

Follow
AIM:AMYT

Price: 180 GBX

Market Cap: £569.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE falls as Deliveroo fails to deliver on listing debut

FTSE 100 slipped back after US stocks were pressured by rising treasury yields and inflation concerns. London’s leading index shed 16 points to 6,744 in early dealings with a dismal start to trading by Deliveroo also dampening the mood.   Having been priced at 390p, the bottom of its range,...

on 31/3/21

2 min read